Search research articles
Contact Us
Filters
Showing results (151-160 of 162) with videos related to
Page
of 17
Sort By:
Diabetes & Metabolism
|
February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Jinlan Liao, Amy Kang, Chao Xia, et al.
Clinical Kidney Journal
|
July 12, 2021
Methods and rationale of the DISCOVER CKD global observational study
Roberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
The Medical Journal of Australia
|
November 5, 2019
Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial
N Wah Cheung, Lesley V Campbell, Gregory R Fulcher, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
May 7, 2015
Research Priorities in CKD: Report of a National Workshop Conducted in Australia
Allison Tong, Sally Crowe, Shingisai Chando, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 23, 2025
Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia
Rajiv Agarwal, Masaomi Nangaku, Liming Chen, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Circulation
|
February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
Nan Ye, Meg J Jardine, Megumi Oshima, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 162) with videos related to
Sort By:
Page
of 17
Diabetes & Metabolism
|
February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Jinlan Liao, Amy Kang, Chao Xia, et al.
Clinical Kidney Journal
|
July 12, 2021
Methods and rationale of the DISCOVER CKD global observational study
Roberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
The Medical Journal of Australia
|
November 5, 2019
Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial
N Wah Cheung, Lesley V Campbell, Gregory R Fulcher, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
May 7, 2015
Research Priorities in CKD: Report of a National Workshop Conducted in Australia
Allison Tong, Sally Crowe, Shingisai Chando, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 23, 2025
Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia
Rajiv Agarwal, Masaomi Nangaku, Liming Chen, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Circulation
|
February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
Nan Ye, Meg J Jardine, Megumi Oshima, et al.
Page
of 17